Landscapes / Companies
Blueprint Medicines Corporation not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
2
in active trials · 8 in all
Trials
4 active
21 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Tyrosine kinase inhibitor |
Phase 2/3 | 30 Sep 2032Phase 2/3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Sep 2032 · Phase 2/3 trial completes | ||||
| Also tested for | Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis | ||||
| Open drug page | |||||
— |
Phase 1/2 | Sep 2029Phase 1/2 trial completes | |||
| Next date | Sep 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Non-Small Cell Lung Cancer and 2 more | ||||
| Open drug page | |||||
About
- No active trial
- 6 other drugs
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021